Message from the President

Greetings. Founded as a national hub for cancer treatment and research in 1962, the National Cancer Center (NCC) Japan has led the nation’s cancer medicine and research ever since. NCC Japan was designated as Incorporated Administrative Agency in 2010, then as a National Research and Development Agency in 2015.

Our organization works across two campuses synergically for cancer treatment and research. In Tsukiji campus we have National Cancer Center Hospital (NCCH), National Cancer Center Research Institute (NCCRI), Institute for Cancer Control (NCC ICC), Center for Cancer Genomics and Advanced Therapeutics (NCC C-CAT), and in Kashiwa campus we have National Cancer Center Hospital East (NCCHE) and Exploratory Oncology Research & Clinical Trial Center (NCC EPOC).

Designated as core hospitals for clinical research in 2015, followed by as core hospitals for cancer genomic medicine in 2018, together NCCH and NCCHE strongly commit to establish a standard of care in Japan, accelerating a cancer genomic medicine, and leading world-class clinical trials and tests for innovative drugs and medical devices.

NCCRI is one of the largest cancer research institutions which dedicates itself to not only cutting-edge research in basic and practical phases, but also to a drug development in collaboration with the hospitals. NCC ICC contributes in cancer epidemiology research, cancer registry, and providing reliable cancer information services. NCC C-CAT is well known to take an initiative to promote a cancer genomic medicine in Japan as a core data center. NCC EPOC focuses on development of innovative anticancer drugs and medical devices. In addition, we have the Center of Promotion of Translational Research (CPOT) which is a cross-functional organization to promote academic research seeds inside and outside NCC Japan to a practical usage for patients.

As you have seen, NCC is not only one of Japan’s major cancer-specialized medical and research institutes, but an institute that promotes medicine globally by collaborating its various divisions with diverse roles. Currently, one in two Japanese will develop cancer in their lifetime. We will do our best to make sure all patients in Japan receive the latest medical care constantly, and to solve drug lag and loss issues as much as possible. We thank your support and encouragement for NCC in advance.

Hiroyuki Mano, M.D., Ph.D.

President,

National Cancer Center Japan